Pharma group estimates Camizestrant could be worth up to $5bn of sales in its peak year
If successful, it would be the first new class of drug against certain bacteria strains for more than 50 years
The Enhanced Games spotlight a growing interest in drugs not only to improve performance, but also to treat depression
Child suffering from rare liver disease shows improved health after treatment
Danish company has had some poor results for new drugs designed to replace treatments when they go off patent
Swiss group becomes latest pharmaceutical company to promise investment in the face of potential tariffs
Promising late-stage trial results lift US pharmaceutical group’s shares almost 15%
US pharmaceutical group says patient in study experienced ‘potential drug-induced liver injury’
Move comes as government seeks to boost UK’s standing as drugs research leader
Acquisitions hold cure for pharma companies’ chronic patent cliff problem
AI unit is boosted by first external funding round led by OpenAI-backer Thrive Capital
The health benefits could be so extreme that it upends the annuity market, hitting retirement incomes and insurers
London-listed drugmaker will establish research centre in Beijing
Academic institutions have frozen new hires and limited PhD places
Pharmaceutical groups are rushing to dominate market that will grow to 900mn people by 2030
Swiss pharma group signs $5.3bn licensing agreement for next-generation treatment made by Zealand Pharma
Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next year
Mental health treatments face higher regulatory hurdles for approval, warns Imperial College professor
BioArctic is developing a process to allow drugs to cross the layer of cells that protects the brain
Research highlights growing focus on surrounding tissues to help tackle most malignant forms of the disease
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
A battle over how to treat childhood obesity is brewing between those in favour and others who warn of the effects on growing bodies
Drugmaker pins hopes on launch of new medicines but key point is to avoid re-traumatising investors
The San Francisco-based start-up plans to get its first drug into trials this year
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis
